<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en-US">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="google-site-verification" content="lRfuoa8xCBWzd--gR2GEwdMnf75tXxXuEC-t4VnUAc4" />
<link rel="stylesheet" type="text/css" media="all" href="https://marketbeat.com/scripts/modal/modernpopup.css"/>
<link rel="pingback" href="https://finexaminer.com/xmlrpc.php" />
<title>Syros Pharmaceuticals Inc. (SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR) Comparing side by side &#8211; The Financial Examiner</title>
<link rel='dns-prefetch' href='//fonts.googleapis.com' />
<link rel='dns-prefetch' href='//s.w.org' />
<link rel="alternate" type="application/rss+xml" title="The Financial Examiner &raquo; Feed" href="https://finexaminer.com/feed/" />
<link rel="alternate" type="application/rss+xml" title="The Financial Examiner &raquo; Comments Feed" href="https://finexaminer.com/comments/feed/" />
<link rel="alternate" type="application/rss+xml" title="The Financial Examiner &raquo; Syros Pharmaceuticals Inc. (SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR) Comparing side by side Comments Feed" href="https://finexaminer.com/2019/03/02/syros-pharmaceuticals-inc-syrs-and-proqr-therapeutics-n-v-nasdaqprqr-comparing-side-by-side/feed/" />
<script type="text/javascript">
window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/11\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/11\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/finexaminer.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=5.0.3"}};
!function(a,b,c){function d(a,b){var c=String.fromCharCode;l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,a),0,0);var d=k.toDataURL();l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,b),0,0);var e=k.toDataURL();return d===e}function e(a){var b;if(!l||!l.fillText)return!1;switch(l.textBaseline="top",l.font="600 32px Arial",a){case"flag":return!(b=d([55356,56826,55356,56819],[55356,56826,8203,55356,56819]))&&(b=d([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]),!b);case"emoji":return b=d([55358,56760,9792,65039],[55358,56760,8203,9792,65039]),!b}return!1}function f(a){var c=b.createElement("script");c.src=a,c.defer=c.type="text/javascript",b.getElementsByTagName("head")[0].appendChild(c)}var g,h,i,j,k=b.createElement("canvas"),l=k.getContext&&k.getContext("2d");for(j=Array("flag","emoji"),c.supports={everything:!0,everythingExceptFlag:!0},i=0;i<j.length;i++)c.supports[j[i]]=e(j[i]),c.supports.everything=c.supports.everything&&c.supports[j[i]],"flag"!==j[i]&&(c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&c.supports[j[i]]);c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&!c.supports.flag,c.DOMReady=!1,c.readyCallback=function(){c.DOMReady=!0},c.supports.everything||(h=function(){c.readyCallback()},b.addEventListener?(b.addEventListener("DOMContentLoaded",h,!1),a.addEventListener("load",h,!1)):(a.attachEvent("onload",h),b.attachEvent("onreadystatechange",function(){"complete"===b.readyState&&c.readyCallback()})),g=c.source||{},g.concatemoji?f(g.concatemoji):g.wpemoji&&g.twemoji&&(f(g.twemoji),f(g.wpemoji)))}(window,document,window._wpemojiSettings);
</script>
<style type="text/css">
img.wp-smiley,
img.emoji {
display: inline !important;
border: none !important;
box-shadow: none !important;
height: 1em !important;
width: 1em !important;
margin: 0 .07em !important;
vertical-align: -0.1em !important;
background: none !important;
padding: 0 !important;
}
</style>
<!-- <link rel='stylesheet' id='wp-block-library-css'  href='https://finexaminer.com/wp-includes/css/dist/block-library/style.min.css?ver=5.0.3' type='text/css' media='all' /> -->
<!-- <link rel='stylesheet' id='wpz-shortcodes-css'  href='https://finexaminer.com/wp-content/themes/yamidoo/functions/wpzoom/assets/css/shortcodes.css?ver=5.0.3' type='text/css' media='all' /> -->
<!-- <link rel='stylesheet' id='zoom-font-awesome-css'  href='https://finexaminer.com/wp-content/themes/yamidoo/functions/wpzoom/assets/css/font-awesome.min.css?ver=5.0.3' type='text/css' media='all' /> -->
<!-- <link rel='stylesheet' id='yamidoo-style-css'  href='https://finexaminer.com/wp-content/themes/yamidoo/style.css?ver=2.0.10' type='text/css' media='all' /> -->
<link rel="stylesheet" type="text/css" href="//finexaminer.com/wp-content/cache/wpfc-minified/2b6lq05v/7tmno.css" media="all"/>
<link rel='stylesheet' id='google-fonts-css'  href='https://fonts.googleapis.com/css?family=Prata%7CDroid+Serif%3A400%2C700%2C400italic%2C700italic&#038;ver=5.0.3' type='text/css' media='all' />
<!-- <link rel='stylesheet' id='wzslider-css'  href='https://finexaminer.com/wp-content/themes/yamidoo/functions/wpzoom/assets/css/wzslider.css?ver=5.0.3' type='text/css' media='all' /> -->
<!-- <link rel='stylesheet' id='wpzoom-custom-css'  href='https://finexaminer.com/wp-content/themes/yamidoo/custom.css?ver=5.0.3' type='text/css' media='all' /> -->
<link rel="stylesheet" type="text/css" href="//finexaminer.com/wp-content/cache/wpfc-minified/ee3yfvge/7tmno.css" media="all"/>
<script src='//finexaminer.com/wp-content/cache/wpfc-minified/98w0qiqj/7tmnp.js' type="text/javascript"></script>
<!-- <script type='text/javascript' src='https://finexaminer.com/wp-includes/js/jquery/jquery.js?ver=1.12.4'></script> -->
<!-- <script type='text/javascript' src='https://finexaminer.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=1.4.1'></script> -->
<!-- <script type='text/javascript' src='https://finexaminer.com/wp-content/themes/yamidoo/js/init.js?ver=5.0.3'></script> -->
<link rel='https://api.w.org/' href='https://finexaminer.com/wp-json/' />
<link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://finexaminer.com/xmlrpc.php?rsd" />
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="https://finexaminer.com/wp-includes/wlwmanifest.xml" /> 
<link rel='prev' title='Reviewing OncoCyte Corporation (OCX)&#8217;s and Savara Inc. (NASDAQ:SVRA)&#8217;s results' href='https://finexaminer.com/2019/03/02/reviewing-oncocyte-corporation-ocxs-and-savara-inc-nasdaqsvras-results/' />
<meta name="generator" content="WordPress 5.0.3" />
<link rel="canonical" href="https://finexaminer.com/2019/03/02/syros-pharmaceuticals-inc-syrs-and-proqr-therapeutics-n-v-nasdaqprqr-comparing-side-by-side/" />
<link rel='shortlink' href='https://finexaminer.com/?p=1887487' />
<link rel="alternate" type="application/json+oembed" href="https://finexaminer.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ffinexaminer.com%2F2019%2F03%2F02%2Fsyros-pharmaceuticals-inc-syrs-and-proqr-therapeutics-n-v-nasdaqprqr-comparing-side-by-side%2F" />
<link rel="alternate" type="text/xml+oembed" href="https://finexaminer.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ffinexaminer.com%2F2019%2F03%2F02%2Fsyros-pharmaceuticals-inc-syrs-and-proqr-therapeutics-n-v-nasdaqprqr-comparing-side-by-side%2F&#038;format=xml" />
<meta name="author" content="41"><meta name="description" content="As Biotechnology businesses, Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR), are affected by contrast. This especially"><meta name="contentType" content="article"><meta name="news_keywords" content="Syros Pharmaceuticals Inc., Syros Pharmaceuticals Inc. - (NASDAQ:SYRS), NASDAQ:SYRS, Gross Revenue, Price/Sales Ratio, Net Income, Earnings Per Share, Price/Earnings Ratio, Net Margins, Return on Equity, Return on Assets, Institutional Ownership, Analyst Recommendations, Profitability, Risk, Dividends, Earnings and Valuation"><meta name="keywords" content="Syros Pharmaceuticals Inc., Syros Pharmaceuticals Inc. - (NASDAQ:SYRS), NASDAQ:SYRS, Gross Revenue, Price/Sales Ratio, Net Income, Earnings Per Share, Price/Earnings Ratio, Net Margins, Return on Equity, Return on Assets, Institutional Ownership, Analyst Recommendations, Profitability, Risk, Dividends, Earnings and Valuation"><meta name="ticker" content="NASDAQ:SYRS"><meta name="wp_post_thumbnail" content=""><meta name="xyz_twap" content="1"><meta name="_encloseme" content="1"><!-- Markup (JSON-LD) structured in schema.org ver.4.6.2 START -->
<script type="application/ld+json">
{
"@context": "http://schema.org",
"@type": "NewsArticle",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://finexaminer.com/2019/03/02/syros-pharmaceuticals-inc-syrs-and-proqr-therapeutics-n-v-nasdaqprqr-comparing-side-by-side/"
},
"headline": "Syros Pharmaceuticals Inc. (SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR) Comparing side by side",
"datePublished": "2019-03-02T04:45:30+0000",
"dateModified": "2019-03-02T04:45:29+0000",
"author": {
"@type": "Person",
"name": "Maria Robertson"
},
"description": "As Biotechnology businesses, Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR",
"publisher": {
"@type": "Organization",
"name": "The Financial Examiner",
"logo": {
"@type": "ImageObject",
"url": "https://finexaminer.com/333.png",
"width": 249,
"height": 51
}
}
}
</script>
<!-- Markup (JSON-LD) structured in schema.org END -->
<!-- WPZOOM Theme / Framework -->
<meta name="generator" content="Yamidoo Magazine 2.0.10" />
<meta name="generator" content="WPZOOM Framework 1.7.0" />
<style type="text/css">@import url("https://fonts.googleapis.com/css?family=Quattrocento|Quattrocento|Quattrocento|Quattrocento|Quattrocento");
#logo h1 a{color:#7eb900;}
.widget h3.title, #sidebar .tabberlive, #articles .head_title, h3.archive_title, .post_author, ul.dropdown li ul{background:#fff;}
.widget h3.title, #sidebar .tabberlive, #articles .head_title, h3.archive_title, ul.dropdown li ul{border-color:#fff;}
body{font-family: 'Quattrocento';font-size: 14px;}#logo h1 a{font-family: 'Quattrocento';font-weight: bold;}.article h2.title a{font-family: 'Quattrocento';font-size: 23px;font-weight: bold;}.single .post h1.title a{font-family: 'Quattrocento';font-size: 34px;font-weight: bold;}.widget h3.title{font-family: 'Quattrocento';}</style>
<script type="text/javascript">document.write('<style type="text/css">.tabber{display:none;}</style>');</script>      <meta name="onesignal" content="wordpress-plugin"/>
<link rel="manifest"
href="https://finexaminer.com/wp-content/plugins/onesignal-free-web-push-notifications/sdk_files/manifest.json.php?gcm_sender_id="/>
<script src="https://cdn.onesignal.com/sdks/OneSignalSDK.js" async></script>    <script>
window.OneSignal = window.OneSignal || [];
OneSignal.push( function() {
OneSignal.SERVICE_WORKER_UPDATER_PATH = "OneSignalSDKUpdaterWorker.js.php";
OneSignal.SERVICE_WORKER_PATH = "OneSignalSDKWorker.js.php";
OneSignal.SERVICE_WORKER_PARAM = { scope: '/' };
OneSignal.setDefaultNotificationUrl("https://finexaminer.com");
var oneSignal_options = {};
window._oneSignalInitOptions = oneSignal_options;
oneSignal_options['wordpress'] = true;
oneSignal_options['appId'] = 'c0dbeaca-d25d-4d33-b4cc-0071edc2044b';
oneSignal_options['autoRegister'] = true;
oneSignal_options['welcomeNotification'] = { };
oneSignal_options['welcomeNotification']['title'] = "Join Wall Street&#039;s Brightest Minds.";
oneSignal_options['welcomeNotification']['message'] = "Receive research in your inbox from top analysts, before the market opens. Click here to learn how.";
oneSignal_options['welcomeNotification']['url'] = "https://www.marketbeat.com/subscribe/subscribe.aspx?ReferralType=OneSignalThankYou&amp;ProductCode=1997t";
oneSignal_options['path'] = "https://finexaminer.com/wp-content/plugins/onesignal-free-web-push-notifications/sdk_files/";
oneSignal_options['safari_web_id'] = "web.onesignal.auto.4ed285de-faf5-4c6c-a346-3ff91e5aded6";
oneSignal_options['promptOptions'] = { };
OneSignal.init(window._oneSignalInitOptions);
});
function documentInitOneSignal() {
var oneSignal_elements = document.getElementsByClassName("OneSignal-prompt");
var oneSignalLinkClickHandler = function(event) { OneSignal.push(['registerForPushNotifications']); event.preventDefault(); };        for(var i = 0; i < oneSignal_elements.length; i++)
oneSignal_elements[i].addEventListener('click', oneSignalLinkClickHandler, false);
}
if (document.readyState === 'complete') {
documentInitOneSignal();
}
else {
window.addEventListener("load", function(event){
documentInitOneSignal();
});
}
</script>
<style type="text/css" id="custom-background-css">
body.custom-background { background-image: url("https://finexaminer.com/wp-content/uploads/2019/01/bgi6.png"); background-position: left top; background-size: cover; background-repeat: no-repeat; background-attachment: fixed; }
</style>
<style type="text/css" id="wp-custom-css">
.widget h3.title, #sidebar .tabberlive, #articles .head_title, h3.archive_title, ul.dropdown li ul {
text-align: center;
border-top:0px;
}
.hr {
border-top: 0px solid #EEE;
}
#logo {
margin: 0 0 0px;
padding-top: 10px;
padding-bottom: 10px;
}
#columns {
margin: 0px 0 0px;
}
#footer .widget-area {
padding: 0 0 0px;
margin: 0 0px;
border-bottom: 0px solid #ececec;
}
#footer {
background-color: #fff;
text-align:center;
}
.post h1.title {
text-align: center;
}		</style>
<script type="text/javascript" src="https://www.marketbeat.com/Scripts/lowerrightad.js"></script>
</head>
<body class="post-template-default single single-post postid-1887487 single-format-standard custom-background">
<div id="page-wrap">
<div id="main-wrap">
<div id="header">
<div id="topmenu">
</div> <!-- /#topmenu -->
<div class="clear"></div>
<div id="logo">
<h1>
<a href="https://finexaminer.com" title="">
The Financial Examiner					</a><div class="clear"></div>
</h1>
</div><!-- / #logo -->
<div id="mainmenu">
<ul id="menu" class="dropdown"><li id="menu-item-1422442" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1422442"><a href="https://finexaminer.com">Trending</a></li>
<li id="menu-item-1526428" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1526428"><a href="https://finexaminer.com/business-news/">Business News</a></li>
<li id="menu-item-1564604" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1564604"><a href="https://finexaminer.com/economy-news/">Economy News</a></li>
<li id="menu-item-1564605" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1564605"><a href="https://finexaminer.com/finance-news/">Finance News</a></li>
</ul>
</div> <!-- /#menu -->
</div> <!--/#header -->
<div class="clear"></div>
<div id="content-wrap">
<div id="main">
<div id="post-1887487" class="post-1887487 post type-post status-publish format-standard hentry category-stock-news">
<h1 class="title"><a href="https://finexaminer.com/2019/03/02/syros-pharmaceuticals-inc-syrs-and-proqr-therapeutics-n-v-nasdaqprqr-comparing-side-by-side/" rel="bookmark" title="Permanent Link to Syros Pharmaceuticals Inc. (SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR) Comparing side by side">Syros Pharmaceuticals Inc. (SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR) Comparing side by side</a></h1>
<span class="post-meta">
Posted by <a href="https://finexaminer.com/author/dford/" title="Posts by Maria Robertson" rel="author">Maria Robertson</a>
on March 2, 2019 at 4:45 am
</span>
<div class="entry">
<div class="entry-content">
<!-- Quick Adsense WordPress Plugin: http://quickadsense.com/ -->
<div style="float: left; margin: 10px 10px 10px 0;">
<script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<!-- finexaminer.com 300x600 -->
<ins class="adsbygoogle" style="display: inline-block; width: 300px; height: 600px;" data-ad-client="ca-pub-8821591761890381" data-ad-slot="6952380149"></ins>
<script>
(adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<p>As Biotechnology businesses, Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and ProQR Therapeutics N.V. (NASDAQ:PRQR), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. </p>
<p><b>Earnings &#038; Valuation</b></p>
<table>
<tbody>
<tr>
<td></td>
<td>Gross Revenue</td>
<td>Price/Sales Ratio</td>
<td>Net Income</td>
<td>Earnings Per Share</td>
<td>Price/Earnings Ratio</td>
</tr>
<tr>
<td>Syros Pharmaceuticals Inc.</td>
<td>1.16M</td>
<td>203.91</td>
<td>59.55M</td>
<td>-1.95</td>
<td>0.00</td>
<tr>
<td>ProQR Therapeutics N.V.</td>
<td>N/A</td>
<td>0.00</td>
<td>N/A</td>
<td>-1.29</td>
<td>0.00</td>
</tbody>
</table>
<p> Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Syros Pharmaceuticals Inc. and ProQR Therapeutics N.V.    </p>
<p><b>Profitability</b></p>
<p> Table 2 provides the return on assets, net margins and return on equity of the two firms. </p>
<table>
<tbody>
<tr>
<td></td>
<td>Net Margins</td>
<td>Return on Equity</td>
<td>Return on Assets</td>
</tr>
<tr>
<td>Syros Pharmaceuticals Inc.</td>
<td>-5,133.62%</td>
<td>-63.8%</td>
<td>-51.9%</td>
</tr>
<tr>
<td>ProQR Therapeutics N.V.</td>
<td>0.00%</td>
<td>-72.6%</td>
<td>-56%</td>
</tr>
</tbody>
</table>
<p><b>Liquidity</b></p>
<p> Syros Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 5.4 and 5.4 respectively. The Current Ratio and Quick Ratio of its competitor ProQR Therapeutics N.V. are 11.4 and 11.4 respectively. ProQR Therapeutics N.V. therefore has a better chance of paying off short and long-term obligations compared to Syros Pharmaceuticals Inc.     </p>
<p><b>Analyst Ratings</b></p>
<p> Recommendations and Ratings for Syros Pharmaceuticals Inc. and ProQR Therapeutics N.V. can be find in next table. </p>
<table>
<tbody>
<tr>
<td></td>
<td>Sell Ratings</td>
<td>Hold Ratings</td>
<td>Buy Ratings</td>
<td>Rating Score</td>
</tr>
<tr>
<td>Syros Pharmaceuticals Inc.</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>ProQR Therapeutics N.V.</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>3.00</td>
</tr>
</tbody>
</table>
<p>  Competitively the consensus target price of ProQR Therapeutics N.V. is $31.67, which is potential 119.93% upside.  </p>
<p><b>Insider and Institutional Ownership</b></p>
<p> Syros Pharmaceuticals Inc. and ProQR Therapeutics N.V. has shares owned by institutional investors as follows: 75.9% and 63.5%. Insiders owned 1.4% of Syros Pharmaceuticals Inc. shares. Competitively, 20.62% are ProQR Therapeutics N.V.&#8217;s share owned by insiders. </p>
<p><b>Performance</b></p>
<p> In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. </p>
<table>
<tbody>
<tr>
<td></td>
<td>Performance (W)</td>
<td>Performance (M)</td>
<td>Performance (Q)</td>
<td>Performance (HY)</td>
<td>Performance (Y)</td>
<td>Performance (YTD)</td>
</tr>
<tr>
<td>Syros Pharmaceuticals Inc.</td>
<td>18.8%</td>
<td>4.93%</td>
<td>-31.5%</td>
<td>-35.64%</td>
<td>-37.17%</td>
<td>-16.86%</td>
</tr>
<tr>
<td>ProQR Therapeutics N.V.</td>
<td>-10.44%</td>
<td>-15.07%</td>
<td>-8.47%</td>
<td>162.62%</td>
<td>478.64%</td>
<td>429.3%</td>
</tr>
</tbody>
</table>
<p>  For the past year Syros Pharmaceuticals Inc. had bearish trend while ProQR Therapeutics N.V. had bullish trend. </p>
<p><b>Summary</b></p>
<p> On 6 of the 10 factors ProQR Therapeutics N.V. beats Syros Pharmaceuticals Inc. </p>
<p>Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. Its lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.</p>
<p>ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber&#x27;s congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.</p>
<!-- Quick Adsense WordPress Plugin: http://quickadsense.com/ -->
<div style="float: none; margin:10px 0 10px 0; text-align:center;">
<a href="https://green.cannabisstocktrades.com/my-2019-stock-pick?a_aid=octafinance&a_bid=4d487c02" target="_top"><img src="https://finexaminer.com/free-report.png" alt="" title=""  "  /></a>
<img style="border:0" src="http://broadcast.ino.com/affiliate/scripts/imp.php?a_aid=octafinance&a_bid=5a4efa9e" width="1" height="1" alt="" />
<p style="clear:both"><strong>Receive News & Ratings Via Email</strong> - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.</p>
<form method="get" action="http://www.marketbeat.com/newsletter/default.aspx">
<input id="BelowPostRegistrationEmail" name="RegisterEmail" placeholder="Your Email Address" class="signup">
<input type="hidden" id="Hidden1" name="RegistrationCode" value="MBAP-Footer-finexaminer">
<input type="submit" name="submit" onclick="return CheckEmail('BelowPostRegistrationEmail','ShowSuggestionFooter');" value="Sign-Up Now (Free)" class="buttonblack">
</form>			
<!-- End Footer Opt-In -->	
<!--Smartad # 4490: finexaminer.com 754x787-->
<iframe WIDTH="754" HEIGHT="787" SCROLLING="NO" src="//www.dianomi.com/smartads.epl?id=4490"  style="width:  100%; height: 787px; border: none; overflow: hidden;"></iframe>
</div>
<div style="font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;"></div>				
<!-- Start Popup -->
<script language="javascript" type="text/javascript" src="https://www.marketbeat.com/scripts/modal/generic/affiliatepopupgeneric.js"></script>
<script type="text/javascript">LoadPopupRatings('MBAP-Popup-finexaminer', 'NASDAQ:SYRS', 'Syros Pharmaceuticals Inc.', 'https://finexaminer.com/333.png');</script>
<!--End Popup -->
</div>
<div class="clear"></div>
<div class="clear"></div>
</div>
<div class="clear"></div>
<div class="clear"></div>
</div><!-- /.post -->
</div><!-- /#main -->
<div id="sidebar">
<div id="text-2" class="widget widget_text">			<div class="textwidget"><p><!--Smartad # 4489: finexaminer.com 336x670--><br />
<iframe style="width:100%; height: 670px; border: none; overflow: hidden;" src="//www.dianomi.com/smartads.epl?id=4489" scrolling="NO"></iframe><br />
<script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><br />
<!-- finexaminer 336x280 --><br />
<ins class="adsbygoogle"
style="display:inline-block;width:336px;height:280px"
data-ad-client="ca-pub-8821591761890381"
data-ad-slot="7199792158"></ins><br />
<script>
(adsbygoogle = window.adsbygoogle || []).push({});
</script></p>
</div>
</div><div id="text-7" class="widget widget_text">			<div class="textwidget"><p><a href="https://green.cannabisstocktrades.com/my-2019-stock-pick?a_aid=octafinance&amp;a_bid=4d487c02" target="_top"><img src="https://quotes.ino.com/img/sites/ino/email/10144.jpg" alt="" title="" width="300" height="250" /></a><img style="border:0" src="http://broadcast.ino.com/affiliate/scripts/imp.php?a_aid=octafinance&amp;a_bid=4d487c02" width="1" height="1" alt="" /></p>
</div>
</div><div id="sidebar_left"></div><div id="sidebar_right"></div>
</div> <!-- /#sidebar -->
		<div class="clear"></div>
</div> <!-- /#content-wrap -->
<div class="clear"></div>
</div> <!-- /#main-wrap -->
<div id="footer">
<div class="widget-area">
<div class="column">
</div><!-- / .column -->
<div class="column">
</div><!-- / .column -->
<div class="column last">
</div><!-- / .column -->
<div class="clear"></div>
</div><!-- /.widget-area-->
<div class="clear"></div>
<div id="footer_right">
<ul id="menu-footer" class=""><li id="menu-item-27566" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-27566"><a href="https://finexaminer.com">Home</a></li>
<li id="menu-item-27576" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-27576"><a href="https://finexaminer.com/about-us/">About US</a></li>
<li id="menu-item-1476948" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1476948"><a href="https://finexaminer.com/our-staff/">Our Staff</a></li>
<li id="menu-item-27579" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-27579"><a href="https://finexaminer.com/contact/">Contact</a></li>
<li id="menu-item-27574" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-27574"><a href="https://finexaminer.com/privacy-policy/">Privacy Policy</a></li>
<li id="menu-item-27575" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-27575"><a href="https://finexaminer.com/comment-policy/">Comment Policy</a></li>
</ul>
Copyright &copy; 2019 &mdash; <a href="https://finexaminer.com/" class="on">The Financial Examiner</a>. All Rights Reserved.		</div>
</div> <!-- /#footer -->
<div class="clear"></div>
</div> <!-- /#page-wrap -->
<script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script><script>(function($){$(document).ready(function(){});})(jQuery);</script><script type='text/javascript' src='https://finexaminer.com/wp-includes/js/comment-reply.min.js?ver=5.0.3'></script>
<script type='text/javascript' src='https://finexaminer.com/wp-content/themes/yamidoo/js/dropdown.js?ver=2.0.10'></script>
<script type='text/javascript' src='https://finexaminer.com/wp-content/themes/yamidoo/js/tabs.js?ver=2.0.10'></script>
<script type='text/javascript' src='https://finexaminer.com/wp-content/themes/yamidoo/js/slider.js?ver=2.0.10'></script>
<script type='text/javascript' src='https://finexaminer.com/wp-content/themes/yamidoo/functions/wpzoom/assets/js/galleria.js'></script>
<script type='text/javascript' src='https://finexaminer.com/wp-content/themes/yamidoo/functions/wpzoom/assets/js/wzslider.js'></script>
<script type='text/javascript' src='https://finexaminer.com/wp-includes/js/wp-embed.min.js?ver=5.0.3'></script>
<script src="//static.getclicky.com/js" type="text/javascript"></script>
<script type="text/javascript">try{ clicky.init(101137845); }catch(e){}</script>
<noscript><p><img alt="Clicky" width="1" height="1" src="//in.getclicky.com/101137845ns.gif" /></p></noscript>
</body>
</html><!-- WP Fastest Cache file was created in 1.41181707382 seconds, on 02-03-19 4:45:32 --><!-- via php -->